EUVIMEDEUVIMED entdecken
Open Access

Bifunctional cancer cell–based vaccine concomitantly drives direct tumor killing and antitumor immunity

Kok-Siong Chen iD, Clemens Reinshagen iD, Thijs A Van Schaik iD, Filippo Rossignoli iD, Paulo Borges, Natalia Claire Mendonca, Reza Abdi iD, Brennan Simon iD, David A Reardon iD, Hiroaki Wakimoto iD, Khalid Shah iD

Science Translational Medicine · 04.01.2023 · 15 (677)

DOI: 10.1126/scitranslmed.abo4778 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 04.01.2023. Verfasst von Kok-Siong Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Stem Cell and Translational Immunotherapy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Cancer Vaccines, Herpesvirus 1, Human, Glioblastoma. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The administration of inactivated tumor cells is known to induce a potent antitumor immune response; however, the efficacy of such an approach is limited by its inability to kill tumor cells before inducing the immune responses. Unlike inactivated tumor cells, living tumor cells have the ability to track and target tumors. Here, we developed a bifunctional whole cancer cell–based therapeutic with direct tumor killing and immunostimulatory roles. We repurposed the tumor cells from interferon-β (IFN-β) sensitive to resistant using CRISPR-Cas9 by knocking out the IFN-β–specific receptor and subsequently engineered them to release immunomodulatory agents IFN-β and granulocyte-macrophage colony-stimulating factor. These engineered therapeutic tumor cells (ThTCs) eliminated established glioblastoma tumors in mice by inducing caspase-mediated cancer cell apoptosis, down-regulating cancer-associated fibroblast-expressed platelet-derived growth factor receptor β, and activating antitumor immune cell trafficking and antigen-specific T cell activation signaling. This mechanism-based efficacy of ThTCs translated into a survival benefit and long-term immunity in primary, recurrent, and metastatic cancer models in immunocompetent and humanized mice. The incorporation of a double kill-switch comprising herpes simplex virus–1 thymidine kinase and rapamycin-activated caspase 9 in ThTCs ensured the safety of our approach. Arming naturally neoantigen-rich tumor cells with bifunctional therapeutics represents a promising cell-based immunotherapy for solid tumors and establishes a road map toward clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesHerpesvirus 1, HumanGlioblastomaAnimalsMiceImmunotherapyImmunization

Substanzen

Cancer Vaccines

Autor:innen und Institutionen

  • Center for Stem Cell and Translational Immunotherapy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • Center for Neuro-Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
  • Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02138, USA.

ORCID-Profile: Kok-Siong Chen, Clemens Reinshagen, Thijs A Van Schaik, Filippo Rossignoli, Reza Abdi, Brennan Simon, David A Reardon, Hiroaki Wakimoto, Khalid Shah

Förderung

  • NINDS NIH HHS

Zitieren

APA

Chen, K. S., Reinshagen, C., Van Schaik, T. A., Rossignoli, F., Borges, P., Mendonca, N. C., Abdi, R., Simon, B., Reardon, D. A., Wakimoto, H., & Shah, K. (2023). Bifunctional cancer cell–based vaccine concomitantly drives direct tumor killing and antitumor immunity. Science Translational Medicine, 15(677). https://doi.org/10.1126/scitranslmed.abo4778

Vancouver

Chen KS, Reinshagen C, Van Schaik TA, Rossignoli F, Borges P, Mendonca NC, et al. Bifunctional cancer cell–based vaccine concomitantly drives direct tumor killing and antitumor immunity. Science Translational Medicine. 2023;15(677). doi:10.1126/scitranslmed.abo4778

BibTeX
@article{Chen2023,
  author = {Chen, Kok-Siong and Reinshagen, Clemens and Van Schaik, Thijs A and Rossignoli, Filippo and Borges, Paulo and Mendonca, Natalia Claire and Abdi, Reza and Simon, Brennan and Reardon, David A and Wakimoto, Hiroaki and Shah, Khalid},
  title = {Bifunctional cancer cell–based vaccine concomitantly drives direct tumor killing and antitumor immunity},
  journal = {Science Translational Medicine},
  year = {2023},
  volume = {15},
  number = {677},
  doi = {10.1126/scitranslmed.abo4778}
}
Kostenlos starten →